Redeye comments on Initiator Pharma’s announcement that it has submitted a CTA to the UK authorities for a phase IIa proof-of-concept study of pudafensine in vulvodynia. We view this as an important operational milestone that broadens the company’s focus into female indications, supported by secured financing and a clear clinical path, and believe positive results could unlock substantial value in an underserved market.
LÄS MER
